CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition

Abstract excerpt

Two out of 41 non-small cell lung cancer patients enrolled in a clinical study were found with a somatic CRAF mutation in their tumor, namely CRAF P261A and CRAF P207S . To our knowledge, both mutations are novel in lung cancer and CRAF P261A has not been previously reported in cancer. Expression of CRAF P261A in HEK293T cells and BEAS-2B lung epithelial cells led to increased ERK pathway activation in a...